# A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001

> **NCT02386761** · PHASE1 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 48 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Single Ascending Dose (SAD)
- **DRUG:** Multiple Ascending Dose (MAD)

## Key facts

- **NCT ID:** NCT02386761
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02386761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02386761, "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02386761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*